SPY423.11+2.25 0.53%
DIA339.45+0.67 0.20%
IXIC14,253.27+111.79 0.79%

--UBS Adjusts Eli Lilly's Price Target to $193 From $170, Modeling Higher Probability of Success for Donanemab; Neutral Rating Kept

05/10/2021 07:00

10:55 AM EDT, 05/10/2021 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

Price: 194.13, Change: -1.29, Percent Change: -0.66